Genetic risk evaluation and management after diagnosis of cancer: practice vs promise

15 de novembre

12h

Sala Actes Pau Viladiu

Tectonic advances in precision oncology hold the promise of markedly improving the experience and outcomes of patients diagnosed with cancer. This motivates a pressing need to understand how these advances are translated into practice to improve human health.  I study how treatment decisions are made between patients newly diagnosed with cancer and their clinicians. My research pinpoints the factors that drive patient treatment decisions and outcomes. I also study the factors that influence clinician recommendations and how clinicians navigate the decision-making and communication process. Most recently, I have pivoted to focus on how advances in genetic risk evaluation and management of patients and their families are put into practice. My research has advanced methodologies in population and health systems research. I also develop and evaluate interventions to improve decision-making and accelerate the pace of adoption of advances in precision oncology into practice. I lead the Cancer Surveillance and Outcomes Research Team.  The Cancer Surveillance and Outcomes Research Team (CanSORT) centered at the University of Michigan generates pace-setting research in communication, decision-making, and quality of care for patients with cancer. The goal of this research is to improve the patient experience and maximize health outcomes of treatment and care support into survivorship. The key to the fountain of youth is life-long learning. I am grateful to colleagues, staff, and the patients and clinicians who participate in our research for the opportunity to stay young.

www.drstevenkatz.com